Natco Pharma Ltd Q4 FY25 Earnings Analysis

- The company expects a good year ahead with strong growth this and next year, despite volatility related to major products like Revlimid. - Revenue from Revlimid will see a one-third quantity allocation starting March, impacting quarterly sales distribution. - Domestic launches like Semaglutide (expected March 2026) and possibly Risdiplam (subject to favorable court verdict) are expected to drive growth in India. - Emerging markets (ROW) and Canada businesses are expected to perform well with multiple approvals anticipated. - Agrochemical (Crop Sciences) business targets doubling sales from ~60 crores to 120-150 crores next year aiming for breakeven. - Growth beyond March 2027 may see a significant drop (50-60%) due to patent expiries and price erosions, though pipeline and new launches could offset some decline. - Overall, growth depends heavily on market conditions, product launches, price erosion, and regulatory approvals, with some volatility expected.

- Natco expects good earnings for the current and next year but foresees significant volatility post-March 2027 due to Revlimid price erosion, potentially leading to a 50-60% drop in earnings around that time. - EBITDA margins excluding Revlimid could be around 18-20%, varying by quarter. - R&D is typically 8-10% of revenues, and spending adapts to cash flow. - The company aims to maintain strong earnings before the expected decline post-2027. - Growth is expected from launches in India (e.g., Semaglutide, Risdiplam) and other markets with 7-8 expected approvals in the next year. - Crop science business targets break-even by next year with revenues around ₹120-150 crores. - Natco anticipates strengthening its U.S. and Rest of World (ROW) businesses via acquisitions. - Long-term growth depends heavily on successful new product launches and managing volatility inherent in their model chasing “big jackpots.”

- Natco Pharma is actively looking for acquisitions to deploy its cash reserves, targeting geography-based expansions primarily: - One acquisition to strengthen the U.S. front-end portfolio. - Another acquisition to bolster the Rest of World (ROW) business outside advanced regulated markets. - The company prefers preserving cash for acquisitions rather than distributing high dividends or buybacks. - They are considering both cash and debt as financing options for takeovers. - No specific ongoing capex or expansion plans for manufacturing were discussed, but there is an understanding that acquiring a front-end manufacturing facility in the U.S. could be a strategic move. - Crop science/agrochemical business aims to grow revenue and reach breakeven next year. - R&D spend is expected to range from 8-10% of annual revenue, indicating ongoing investment in pipeline products. Overall, strategic investments are focused on acquisitions and selective manufacturing front-end expansion rather than organic capex.

- Natco Pharma currently has about 3,264 crores of cash and liquidity investments and around 241 crores of debt, leading to a net cash position of about 3,000 crores as of December 31. - The company is open to taking on debt if required for acquisitions but has not committed to any specific debt or equity fundraising at this time. - The management is actively looking for acquisition opportunities and will decide on the mix of cash and debt to fund those acquisitions when they arise. - There is no indication of any immediate equity fundraising. - Dividend payouts are being modest to preserve cash for potential acquisitions. - The company has not ruled out buybacks but currently prioritizes cash usage for acquisitions over returning cash to shareholders. In summary, there is no active fundraising underway, but the company is open to debt for acquisitions and holds substantial cash reserves.

The transcript provided does not specifically mention the current or expected order book or pending orders of Natco Pharma Limited. However, key insights related to business outlook and product launches include: - Expectation of good performance in FY25 and FY26 with multiple product approvals and launches, including in ROW markets like Brazil, Canada, and Middle East. - Revlimid allocation: one-third quantity expected, starting March, which impacts sales and operating margins. - Anticipation of new launches like Semaglutide in India by March 2026, subject to approvals. - 7-8 product approvals expected in the coming year for ROW business. - Focus on acquisitions in the U.S. and rest-of-world markets to enhance business. - Crop science/agrochemical business targeting break-even with revenue around ₹120-150 crores next year. No explicit details on order book or pending orders are disclosed in the transcript.